je.st
news
Tag: percent
13 percent of public school students were chronically absent in 2013-14, federal report says
2016-06-08 17:55:00| American School & University
The Department of Education's Civil Rights Data Collection has compiled national absentee statistics for the first time read more
Tags: report
public
school
says
Chances of La Nina event still 50 percent as Pacific cools: weather bureau
2016-06-07 08:28:00| Climate Ark Climate Change & Global Warming Newsfeed
Reuters: The chances of a La Nina weather event forming later in 2016 are 50 percent, the Australian Bureau of Meteorology (BOM) said on Tuesday, as the tropical Pacific Ocean continues to cool. The bureau had said in May that the strongest El Nino in nearly 20 years - which had damaged crop output in Asia and caused food shortages - had ended. It placed the likelihood of a subsequent La Nina at 50-50, where it remains. "The tropical Pacific Ocean remains in a neutral El Nino-Southern Oscillation (ENSO)...
Tags: event
percent
weather
pacific
KEYTRUDA (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
2016-06-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). These data will be presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 8:00 11:30 a.m. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Hexion Sells its 50 Percent Interest in HA International to Hüttenes-Albertus
2016-06-06 12:11:24| Coatings World Breaking News
Tags: to
international
interest
percent
New Data Evaluating KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
2016-06-04 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed overall response rates (ORR) ranging from 48 to 71 percent, depending on the therapy used. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] next »